BioCryst Pharmaceuticals | BCRX - Current Liabilities


BioCryst Pharmaceuticals reported $195.39M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Chugai Pharma JPY 327.7B 83.38B Mar/2026
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
DBV Technologies USD 58.02M 8.54M Dec/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Incyte USD 1.49B 25.52M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novavax USD 342.46M 117.49M Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026